Does Odonate Therapeutics Inc (ODT) Have What it Takes to be in Your Portfolio Thursday?

Thursday, January 13, 2022 11:11 AM | InvestorsObserver Analysts

Mentioned in this article

Does Odonate Therapeutics Inc (ODT) Have What it Takes to be in Your Portfolio Thursday?

A rating of 43 puts Odonate Therapeutics Inc (ODT) near the middle of the Biotechnology industry according to InvestorsObserver. Odonate Therapeutics Inc's score of 43 means it scores higher than 43% of stocks in the industry. Odonate Therapeutics Inc also received an overall rating of 37, putting it above 37% of all stocks. Biotechnology is ranked 97 out of the 148 industries.

ODT has an Overall Score of 37. Find out what this means to you and get the rest of the rankings on ODT!

See Full ODT Report

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Odonate Therapeutics Inc Stock Today?

Odonate Therapeutics Inc (ODT) stock is flat -0.42% while the S&P 500 has fallen -0.18% as of 10:57 AM on Thursday, Jan 13. ODT is unmoved $0.00 from the previous closing price of $1.18 on volume of 52,246 shares. Over the past year the S&P 500 has risen 23.83% while ODT has fallen -94.08%. ODT lost -$2.72 per share the over the last 12 months. Click Here to get the full Stock Report for Odonate Therapeutics Inc stock.